USA FDA (Food & Drug Administration) has a long history of being one of the hardest markets to get approval for new therapeutics or diagnostic tests. However, it is in process of a technology modernization plan. The EU is a bit faster to get approvala with less duration of human trials required, etc.
However, China may see the benefits of a new biosensor from AXE and under emergency measures may be keen to fast track & apply biosensor trials in the field as soon as possible. This is wishful thinking, but we know that Chinese people have a high level of trust in the quality of Australian health products.
We could be confident that AXE's biosensor JV partner is working 24/7 to bring news to shareholders.
AXE Price at posting:
22.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)